TITLE

Which is the best lipid-modifying strategy in metabolic syndrome and diabetes: fibrates, statins or both?

AUTHOR(S)
Tenenbaum, Alexander; Fisman, Enrique Z.
PUB. DATE
January 2004
SOURCE
Cardiovascular Diabetology;2004, Vol. 3, p1
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Although less clinical intervention studies have been performed with fibrates than with statins, there are evidences indicating that fibrates may reduce risk of cardiovascular events. The potential clinical benefit of the fenofibrate will be specified by the ongoing Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study, which rationale, methods and aims have been just published. Controlled clinical trials show similar or even greater cardiovascular benefits from statins-based therapy in patient subgroups with diabetes compared with overall study populations. Therefore, statins are the drug of first choice for aggressive lipid lowering actions and reducing risk of coronary artery disease in these patients. However, current therapeutic use of statins as monotherapy is still leaving many patients with mixed atherogenic dyslipidemia at high risk for coronary events. A combination statin/fibrate therapy may be often necessary to control all lipid abnormalities in patients with metabolic syndrome and diabetes adequately, since fibrates provide additional important benefits, particularly on triglyceride and HDL-cholesterol levels. Thus, this combined therapy concentrates on all the components of the mixed dyslipidemia that often occurs in persons with diabetes or metabolic syndrome, and may be expected to reduce cardiovascular morbidity and mortality. Safety concerns about some fibrates such as gemfibrozil may lead to exaggerate precautions regarding fibrate administration and therefore diminish the use of the seagents. However, other fibrates, such as bezafibrate and fenofibrate appear to be safer and better tolerated. We believe that a proper co-administration of statins and fibrates, selected on basis of their safety, could be more effective in achieving a comprehensive lipid control as compared with monotherapy.
ACCESSION #
28683676

 

Related Articles

  • Evaluation of N-terminal pro-B-type natriuretic peptide and high-sensitivity C-reactive protein relationship with features of metabolic syndrome in high-risk subgroups for cardiovascular disease. Nayak, Bijoor Shivananda; Jagessar, Avinas; Mohammed, Zaryd; Rampersad, Jarryd; Ramkissoon, Solange; Biswah, Shivonne; Mohammed, Amisha; Maraj, Aneela; Rampersad, Christina // International Journal of Applied & Basic Medical Research;Sep-Dec2015, Vol. 5 Issue 3, p190 

    Aim: This study evaluating N-terminal pro-B-type natriuretic peptide (NT-pro-BNP) and high sensitivity C-reactive protein (hs-CRP) relationship with features of the metabolic syndrome (MS) in high risk subgroups for cardiovascular disease (CVD) in Trinidad. Materials and Methods: The sample...

  • The Metabolic Syndrome: Recognition and Management. Hall, W. Dallas; Watkins, Laurence O.; Wright, Jackson T.; Wenger, Nanette K.; Kumanyika, Shiriki K.; Gavin, James R.; Ferdinand, Keith C.; Watson, Karol; Clark, Luther T.; Flack, John M.; Reed, James W.; Horton, Ella W.; Saunders, Elijah // Disease Management;Feb2006, Vol. 9 Issue 1, p16 

    The National Cholesterol Education Program defines the metabolic syndrome as three or more of five abnormalities: waist circumference of >40 in (102 cm) for men or >35 in (88 cm) for women, triglyceride level of ≥150 mg/dL, high-density lipoprotein cholesterol of <40 mg/dL in men or <50...

  • Prevalence of metabolic syndrome (MetS) in Chinese subjects gradually increased with impaired glucose homeostasis: a multicenter, clinical based, cross-sectional study. Yufei Xiang; Gan Huang; Weidong Zhou; Zhihong Che; Pengcheng Zhou; Zhiguang Zhou // BMC Public Health;2012, Vol. 12 Issue 1, p675 

    Background: Metabolic Syndrome (MetS) is a high risk factor for Cardiovascular Diseases (CVD). We estimated to investigate how MetS prevalence by glucose homeostasis varies across different age and gender groups. Methods: We studied 9257 Chinese subjects over the age of 15 years in two...

  • BENEFIQ 2014...in Canada this fall.  // Nutraceuticals Now;Summer2014, p27 

    The article offers information on the BENEFIQ 2014 conference, International Rendezvous on Health Ingredients, to be held in Quebec City, Quebec on September 23-25, 2014 on topics including cardiovascular diseases, sports nutrition and metabolic syndrome.

  • Osteoprotegerin in Cardiometabolic Disorders. Pérez de Ciriza, C.; Lawrie, A.; Varo, N. // International Journal of Endocrinology;5/11/2015, Vol. 2015, p1 

    Osteoprotegerin (OPG), a glycoprotein traditionally implicated in bone remodelling, has been recently related to cardiovascular disease (CVD). Human studies show a positive relationship between circulating OPG, vascular damage, and CVD, and as such OPG has emerged as a potential biomarker for...

  • The relevance of 'metabolic syndrome' Cradock, Sue // Independent Nurse;3/12/2010, p1 

    The article mentions the definition of metabolic syndrome as given by the International Diabetes Federation (IDF). British Medical Journal (BMJ) commissioned a debate on IDF's definition of the term and later IDF collaborated with the American Heart Association and other organizations such as...

  • Liraglutide improves metabolic parameters and carotid intima-media thickness in diabetic patients with the metabolic syndrome: an 18-month prospective study. Rizzo, Manfredi; Rizvi, Ali A.; Patti, Angelo Maria; Nikolic, Dragana; Giglio, Rosaria Vincenza; Castellino, Giuseppa; Volti, Giovanni Li; Caprio, Massimiliano; Montalto, Giuseppe; Provenzano, Vincenzo; Genovese, Stefano; Ceriello, Antonio // Cardiovascular Diabetology;12/3/2016, Vol. 15, p1 

    Background: Liraglutide, a GLP-1 analogue, exerts several beneficial non-glycemic effects in patients with type-2 diabetes (T2DM), such as those on body weight, blood pressure, plasma lipids and inflammation markers. However, the effects of liraglutide on cardiovascular (CV) risk markers in...

  • Allopurinol Effect on Values of Lipid Profile Fractions in Hyperuricemic Patients Diagnosed with Metabolic Syndrome. Ziga, Nermina; Becic, Fahir // Materia Socio Medica;Sep2013, Vol. 25 Issue 3, p167 

    Subject: The concentration of serum uric acid (SUA) is one of the potential markers of cardiovascular and cerebrovascular diseases, as well as some other severe diseases. In this pharmacological - clinical study we evaluated allopurinol effect on certain values of lipid profile fractions in...

  • The impact of metabolic syndrome on carotid intima media thickness. AYDIN, M.; BULUR, S.; ALEMDAR, R.; YALÇIN, S.; TÜRKER, Y.; BASAR, C.; ASLANTAS, Y.; YAZGAN, Ö.; ALBAYRAK, S.; ÖZHAN, H. // European Review for Medical & Pharmacological Sciences;Sep2013, Vol. 17 Issue 17, p2295 

    OBJECTIVES: Metabolic syndrome (MetS) is a cluster of metabolic abnormalities involving several cardiovascular risk factors. Carotid intima media thickness (CIMT) is an important early screening tool to assess subclinical manifestation of cardiovascular and metabolic diseases. We aimed to...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics